Drug reference

Alectinib

Tyrosine Kinase Inhibitor · Antineoplastic

Also known as Alecensa, Alectinib hydrochloride

Tyrosine Kinase InhibitorAntineoplasticATC null

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

7 major

SEVERE in our sources

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk (toxicity in animal studies).

FDA category + note

Top interactionssee all 9 →

Aminolevulinic AcidSevereDatabaseDDInter
LeflunomideSevereDatabaseDDInter
LomitapideSevereDatabaseDDInter
MipomersenSevereDatabaseDDInter

Mechanism

Alectinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK). It is effective in patients whose non-small cell lung cancer (NSCLC) harbors ALK mutations, including those who have progressed on or become intolerant to first-generation ALK inhibitors.

Indications

ALK-positive advanced non-small cell lung cancer in adultsFirst-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancerlung NSCLC (ALK translocation)advanced or recurrent NSCLC harboring the ALK fusion geneALK+ NSCLC who have progressed on treatment with crizotinib or are intolerant to crizotinibfirst-line treatment of ALK-positive advanced NSCLC

Dosing

Hepatic adjustment: Manufacturer advises avoid in severe impairment; reduce dose in moderate impairment.

Pharmacokinetics

Half-life

33 h

Metabolism

CYP3A4

Contraindications

Severe hepatic impairment

Side effects

Common

anaemiaarthralgiaback painblood creatine phosphokinase increasedconstipationcoughdiarrhoeadizzinessdysgeusiadyspnoeaoedema peripheralfatiguehyperglycaemiahyperkalaemiahyperlipidaemiahyponatraemiahypophosphataemiaincreased blood bilirubinincreased blood alkaline phosphataseincreased blood transaminasesmyalgiamyopathynauseaoesophageal spasmophthalmic disordersoropharyngeal painpain in extremitypolycythaemiaproteinuriaskin reactionstaste alteredthrombocytopeniatinnitusvomitingweight decreasededema

Serious